AC Immune has partner-backed Alzheimer's programs, a Parkinson's active immunotherapy readout, a new NLRP3 Phase 1 asset, and CHF 74.8 million of Q1 2026 cash resources. The hard question is whether 2026 milestones can turn platform promise into partner commitment before the runway becomes the thesis.
References
Sources used in this report
SEC submissionsSEC submissions JSON for CIK 00016516252026-05-13 · Issuer identity, ticker, exchange, SIC, fiscal year end, and filing inventory.SEC XBRL companyfactsSEC companyfacts for CIK 00016516252026-05-13 · Tagged IFRS fact cross-check for cash, financial assets, revenue, loss, and share data.Annual reportFY2025 Form 20-F2026-03-13 · Business model, platforms, pipeline, collaborations, risk factors, financial statements, employees, governance, and foreign private issuer context.Earnings releaseFY2025 financial results and corporate update2026-03-13 · FY2025 cash resources, runway, contract revenue, expenses, net loss, workforce reduction, pipeline focus, and 2026 milestones.Quarterly updateQ1 2026 financial and corporate update2026-04-30 · Latest cash resources, runway, Q1 financials, milestone calendar, partner updates, and program status.Company releaseACI-24 ABATE final cohort and Takeda milestone2026-04-30 · AD4 cohort initiation, $12 million Takeda milestone, ABATE trial design, and Takeda option/license economics.Company releaseLilly Morphomer Tau amendment2026-04-07 · CHF10 million upfront payment, Phase 1 dosing milestone, over CHF1.7 billion potential milestones, royalties, and IND-enabling timing.Company releaseACI-19764 NLRP3 Phase 1 initiation2026-02-24 · First participant dosing, Phase 1 SAD/MAD design, target engagement, and H2 2026 initial data expectation.Company releaseCEO transition announcement2026-05-12 · Founder CEO retirement, interim CEO appointment, advisor role, and succession risk context.Peer annual reportBiogen FY2025 Form 10-K2026-02-06 · Official Alzheimer's market context, LEQEMBI commercialization, and competitive treatment landscape.Peer annual reportEli Lilly FY2025 Form 10-K2026-02-12 · Official large-pharma Alzheimer's competition and partner-scale context.